Palbociclib (P) in combination with fulvestrant (F) or letrozole (L) in endocrine-sensitive patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC): detailed safety analysis from a multicenter, randomized, open-label, phase II trial (PARSIFAL)

Publications

>

Meeting Abstract

Palbociclib (P) in combination with fulvestrant (F) or letrozole (L) in endocrine-sensitive patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC): detailed safety analysis from a multicenter, randomized, open-label, phase II trial (PARSIFAL)

Publicated to:Cancer Research. 81 (4): - 2021-02-01 81(4), DOI: https://doi.org/10.1158/1538-7445.SABCS20-PS10-17

Authors: Perez-Garcia, JM; Llombart-Cussac, A; Bellet, M; Dalenc, F; Gil, MJG; Borrego, MR; Gavila, J; Sampayo-Cordero, M; Aguirre, E; Schmid, P; Marme, F; Di Cosimo, S; Gligorov, J; Schneeweiss, A; Albanell, J; Zamora, P; Wheatley, D; Martinez-De Duenas, E; Caranana, V; Amillano, K; Malfettone, A; Cortes, J

Affiliations

‎ Barts Hosp NHS Trust, London, England - Author

‎ Fdn Inst Valenciano Oncol, Dept Med Oncol, Valencia, Spain - Author

‎ Fdn IRCCS Ist Nazl Tumori, Biomarker Unit, Milan, Italy - Author

‎ German Canc Res Ctr, Natl Ctr Tumor Dis NCT, Heidelberg, Germany - Author

‎ Heidelberg Univ Hosp, Natl Ctr Tumor Dis NCT, Heidelberg, Germany - Author

‎ Hosp Arnau Vilanova, Valencia, Spain - Author

‎ Hosp del Mar, Med Oncol, Barcelona, Spain - Author

‎ Hosp Prov Castellon, Serv Oncol, Castellon de La Plana, Spain - Author

‎ Hosp Tenon, AP HP, Dept Med Oncol, Paris, France - Author

‎ Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain - Author

‎ Hosp Univ St Joan Reus, Reus, Spain - Author

‎ Hosp Univ Virgen del Rocio, Dept Med Oncol, Seville, Spain - Author

‎ IDIBELL, Breast Canc Unit, Inst Catala Oncol, Barcelona, Spain - Author

‎ IDIBELL, Dept Med Oncol, Barcelona, Spain - Author

‎ INSERM, Dept Med Oncol, Inst Claudius Regaud, IUCT Oncopole,CRCT, Toulouse, France - Author

‎ Med Sci Innovat Res MedSIR, Barcelona, Spain - Author

‎ Med Sci Innovat Res MedSIR, Ridgewood, NJ USA - Author

‎ Natl Ctr Tumorerkrankungen, Leitung Sekt Translat Gynakol Onkol, Heidelberg, Germany - Author

‎ Queen Mary Univ London, Barts Canc Inst, Barts ECMC, London, England - Author

‎ QuironSalud Grp, Inst Oncol, IOB, Barcelona, Spain - Author

‎ QuironSalud Grp, Inst Oncol, IOB, Madrid, Spain - Author

‎ Royal Cornwall Hosp NHS Trust, Truro, England - Author

‎ Univ Catolica Valencia, Hosp Arnau de Vilanova, Valencia, Spain - Author

‎ Univ Frauenklin Heidelberg, Heidelberg, Germany - Author

‎ Vall dHebron Inst Oncol VHIO, Barcelona, Spain - Author

‎ Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain - Author

Abstract

Keywords

Astronomia / físicaBiotecnologíaCancer researchCiências biológicas iCiências biológicas iiCiências biológicas iiiFarmaciaGeneral medicineInterdisciplinarMedicina iMedicina iiMedicina iiiMedicina veterinariaOdontologíaOncologyQuímicaSaúde coletiva

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Cancer Research due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 20/245, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology. Notably, the journal is positioned above the 90th percentile.

Impact and social visibility

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: France; Germany; Italy; United Kingdom; United States of America.

Indexed in

License and use

Citations

Altmetrics

Analysis of institutional authors

Share